Developer docs
API playgroundTry for free, no card

Search company profiles

Applied Therapeutics

Full company profile

uuid0000qhk

Namestring
Applied Therapeutics
Legal namestring
Applied Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Applied Therapeutics, Inc. was a clinical-stage biopharmaceutical company that developed govorestat (AT-007), a next-generation, CNS-penetrant, highly selective Aldose Reductase Inhibitor, targeting rare metabolic and neurological diseases with no FDA-approved treatment options — specifically Classic Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and Phosphomannomutase 2 Deficiency (PMM2-CDG). The company pursued regulatory designations that would accelerate development, including FDA Orphan Drug status across all three indications, EMA Orphan Medicinal Product Designations for Galactosemia and SORD Deficiency, Pediatric Rare Disease designations, and FDA Fast Track designation for Galactosemia. The technology platform centered on applying selective ARI pharmacology to CNS-penetrant oral therapy, supported by Phase 3 readouts in the ACTION-Galactosemia Kids study and the INSPIRE trial in SORD Deficiency.

The company was pre-revenue and operated as a clinical development organization, sustaining operations through repeated equity raises totaling more than $400 million cumulatively across private and public rounds, including a $100 million PIPE in February 2024. In November 2024, the FDA issued a Complete Response Letter for the Galactosemia NDA, materially impairing the lead commercial pathway. This was followed by a 46% workforce reduction in November 2025 and acquisition by Cycle Group Holdings Limited, completed in February 2026 at approximately $14.3 million total consideration ($0.088 per share plus contingent value rights). Applied Therapeutics is now an indirect wholly owned subsidiary of Cycle Group Holdings, delisted from Nasdaq. In April 2026, the company announced discontinuation of all active Applied-sponsored govorestat clinical studies and ended the Expanded Access Program in order to re-evaluate development strategy under new ownership.

Short descriptiontext

Applied Therapeutics is a clinical-stage biopharmaceutical company that develops govorestat, a CNS-penetrant Aldose Reductase Inhibitor, for rare metabolic and neurological diseases including Classic Galactosemia, SORD Deficiency, and PMM2-CDG; acquired by Cycle Group Holdings in February 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, aldose reductase inhibitors, clinical-stage biopharmaceuticals, metabolic disease treatments, neurological disease drugs
Industry2 codes
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue would be generated through sales of govorestat and other pipeline products upon regulatory approval. The company was acquired by Cycle Group Holdings in February 2026.

appliedtherapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Applied Therapeutics is a clinical-stage biopharmaceutical company developing govorestat (AT-007), a CNS-penetrant next-generation Aldose Reductase Inhibitor (ARI) for the treatment of rare metabolic and neurological diseases including Classic Galactosemia, SORD Deficiency, and PMM2-CDG. The company leverages expedited regulatory pathways including Orphan Drug, Fast Track, and Pediatric Rare Disease designations to advance its pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 ACTION-Galactosemia Kids study demonstrated clinical benefit on activities of daily living, behavioral symptoms, cognition, fine motor skills and tremor in pediatric patients aged 2-17
+2 more records
Product overview1 text field

Applied Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare metabolic and neurological diseases. The company's primary product is govorestat (AT-007), a CNS-penetrant Aldose Reductase Inhibitor targeting multiple rare conditions including Classic Galactosemia, CMT-SORD, and PMM2-CDG. The company leverages technological advances to target molecules and pathways with proven roles in disease biology, using expedited regulatory pathways where possible. Following acquisition by Cycle Group Holdings Limited in February 2026, Applied Therapeutics operates as a wholly owned subsidiary focused on advancing the govorestat pipeline.

Product and service1 record
1Govorestat (AT-007)
CategoryPrescription Pharmaceutical - Rare Disease Therapeutic
Description

Govorestat (AT-007) is a next-generation, potent and selective oral Aldose Reductase Inhibitor (ARI) being developed for the treatment of multiple rare diseases including Classic Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and Phosphomannomutase 2 Deficiency (PMM2-CDG). It is CNS-penetrant with a highly selective mechanism of action that avoids the off-target effects of historical ARIs, and has received Orphan Drug designation from FDA and EMA for multiple indications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty rare disease pharmaceutical company and now the parent of Applied Therapeutics; directly comparable as a rare-disease-focused commercial-stage company targeting similar patient populations and distribution channels.

TypeDirect peer
Description

Clinical-to-commercial rare disease biotech with multiple orphan programs in metabolic and neurological diseases; closely comparable business model of targeting rare genetic disorders with high unmet need.

TypeDirect peer
Description

Rare disease biopharma with deep pediatric and inherited metabolic disease franchise; directly comparable in commercial strategy for ultra-rare enzyme and metabolic disorder therapeutics.

TypeBroad incumbent
Description

Established rare disease commercial leader (now part of AstraZeneca) with multiple orphan drugs in metabolic, neurological, and genetic diseases; comparable in commercial model and patient access infrastructure.

TypeDirect peer
Description

Specialty rare disease unit of Recordati focused on metabolic and neurological rare disorders; comparable in go-to-market model for ultra-rare pediatric and metabolic disease therapies.

TypeDirect peer
Description

Rare disease biopharma developing therapies for serious rare metabolic and neurological conditions; comparable in business model and patient population targeting.

TypeDirect peer
Description

Genetic rare disease company focused on neuromuscular and inherited disorders; comparable in CNS-penetrant rare disease drug development and orphan regulatory strategy.

TypeEmerging player
Description

Genetic disease-focused biopharma with pipeline assets in rare metabolic and neurological conditions; comparable in targeting genetically defined rare diseases with high unmet need.

TypeEmerging player
Description

Clinical-stage rare disease company developing CNS-penetrant therapies for genetic neurological disorders; comparable in CNS-targeted rare disease drug development approach.

TypeBroad incumbent
Description

Pioneering rare disease commercial franchise within Sanofi; comparable in rare metabolic disease commercialization, specialty distribution, and orphan drug lifecycle management.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Applied Therapeutics

Rare Disease Biopharmaceuticalsappliedtherapeutics.com

Applied Therapeutics is a clinical-stage biopharmaceutical company that develops govorestat, a CNS-penetrant Aldose Reductase Inhibitor, for rare metabolic and neurological diseases including Classic Galactosemia, SORD Deficiency, and PMM2-CDG; acquired by Cycle Group Holdings in February 2026.

What Applied Therapeutics does

Applied Therapeutics, Inc. was a clinical-stage biopharmaceutical company that developed govorestat (AT-007), a next-generation, CNS-penetrant, highly selective Aldose Reductase Inhibitor, targeting rare metabolic and neurological diseases with no FDA-approved treatment options — specifically Classic Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and Phosphomannomutase 2 Deficiency (PMM2-CDG). The company pursued regulatory designations that would accelerate development, including FDA Orphan Drug status across all three indications, EMA Orphan Medicinal Product Designations for Galactosemia and SORD Deficiency, Pediatric Rare Disease designations, and FDA Fast Track designation for Galactosemia. The technology platform centered on applying selective ARI pharmacology to CNS-penetrant oral therapy, supported by Phase 3 readouts in the ACTION-Galactosemia Kids study and the INSPIRE trial in SORD Deficiency.

The company was pre-revenue and operated as a clinical development organization, sustaining operations through repeated equity raises totaling more than $400 million cumulatively across private and public rounds, including a $100 million PIPE in February 2024. In November 2024, the FDA issued a Complete Response Letter for the Galactosemia NDA, materially impairing the lead commercial pathway. This was followed by a 46% workforce reduction in November 2025 and acquisition by Cycle Group Holdings Limited, completed in February 2026 at approximately $14.3 million total consideration ($0.088 per share plus contingent value rights). Applied Therapeutics is now an indirect wholly owned subsidiary of Cycle Group Holdings, delisted from Nasdaq. In April 2026, the company announced discontinuation of all active Applied-sponsored govorestat clinical studies and ended the Expanded Access Program in order to re-evaluate development strategy under new ownership.

Applied Therapeutics firmographics

Firmographics
Name
Applied Therapeutics
Legal name
Applied Therapeutics, Inc.
Website
https://appliedtherapeutics.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Short description
Applied Therapeutics is a clinical-stage biopharmaceutical company that develops govorestat, a CNS-penetrant Aldose Reductase Inhibitor, for rare metabolic and neurological diseases including Classic Galactosemia, SORD Deficiency, and PMM2-CDG; acquired by Cycle Group Holdings in February 2026.
Ownership category
akta.pro rank

Applied Therapeutics industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Aldose reductase inhibitors
  • Clinical-stage biopharmaceuticals
  • Metabolic disease treatments
  • Neurological disease drugs

Where Applied Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Applied Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue would be generated through sales of govorestat and other pipeline products upon regulatory approval. The company was acquired by Cycle Group Holdings in February 2026.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Applied Therapeutics product offering

Product offering

Core offering

Applied Therapeutics is a clinical-stage biopharmaceutical company developing govorestat (AT-007), a CNS-penetrant next-generation Aldose Reductase Inhibitor (ARI) for the treatment of rare metabolic and neurological diseases including Classic Galactosemia, SORD Deficiency, and PMM2-CDG. The company leverages expedited regulatory pathways including Orphan Drug, Fast Track, and Pediatric Rare Disease designations to advance its pipeline.

Product overview

Applied Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare metabolic and neurological diseases. The company's primary product is govorestat (AT-007), a CNS-penetrant Aldose Reductase Inhibitor targeting multiple rare conditions including Classic Galactosemia, CMT-SORD, and PMM2-CDG. The company leverages technological advances to target molecules and pathways with proven roles in disease biology, using expedited regulatory pathways where possible. Following acquisition by Cycle Group Holdings Limited in February 2026, Applied Therapeutics operates as a wholly owned subsidiary focused on advancing the govorestat pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Govorestat (AT-007) Govorestat (AT-007) is a next-generation, potent and selective oral Aldose Reductase Inhibitor (ARI) being developed for the treatment of multiple rare diseases including Classic Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and Phosphomannomutase 2 Deficiency (PMM2-CDG). It is CNS-penetrant with a highly selective mechanism of action that avoids the off-target effects of historical ARIs, and has received Orphan Drug designation from FDA and EMA for multiple indications.

Quantifiable outcome

  • Phase 3 ACTION-Galactosemia Kids study demonstrated clinical benefit on activities of daily living, behavioral symptoms, cognition, fine motor skills and tremor in pediatric patients aged 2-17
  • +2 more outcomes

Companies that use Applied Therapeutics

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Applied Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Applied Therapeutics partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights3 records

Applied Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cycle Pharmaceuticals: Specialty rare disease pharmaceutical company and now the parent of Applied Therapeutics; directly comparable as a rare-disease-focused commercial-stage company targeting similar patient populations and distribution channels.
  • Ultragenyx Pharmaceutical: Clinical-to-commercial rare disease biotech with multiple orphan programs in metabolic and neurological diseases; closely comparable business model of targeting rare genetic disorders with high unmet need.
  • BioMarin Pharmaceutical: Rare disease biopharma with deep pediatric and inherited metabolic disease franchise; directly comparable in commercial strategy for ultra-rare enzyme and metabolic disorder therapeutics.
  • Recordati Rare Diseases: Specialty rare disease unit of Recordati focused on metabolic and neurological rare disorders; comparable in go-to-market model for ultra-rare pediatric and metabolic disease therapies.
  • Travere Therapeutics: Rare disease biopharma developing therapies for serious rare metabolic and neurological conditions; comparable in business model and patient population targeting.
  • Sarepta Therapeutics: Genetic rare disease company focused on neuromuscular and inherited disorders; comparable in CNS-penetrant rare disease drug development and orphan regulatory strategy.

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Established rare disease commercial leader (now part of AstraZeneca) with multiple orphan drugs in metabolic, neurological, and genetic diseases; comparable in commercial model and patient access infrastructure.
  • Genzyme (Sanofi): Pioneering rare disease commercial franchise within Sanofi; comparable in rare metabolic disease commercialization, specialty distribution, and orphan drug lifecycle management.

Emerging players

  • BridgeBio Pharma: Genetic disease-focused biopharma with pipeline assets in rare metabolic and neurological conditions; comparable in targeting genetically defined rare diseases with high unmet need.
  • Taysha Gene Therapies: Clinical-stage rare disease company developing CNS-penetrant therapies for genetic neurological disorders; comparable in CNS-targeted rare disease drug development approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Applied Therapeutics social profiles

Digital presence

Applied Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Applied Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Applied Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Applied Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Applied Therapeutics

What does Applied Therapeutics do?

Applied Therapeutics is a clinical-stage biopharmaceutical company developing govorestat (AT-007), a CNS-penetrant next-generation Aldose Reductase Inhibitor (ARI) for the treatment of rare metabolic and neurological diseases including Classic Galactosemia, SORD Deficiency, and PMM2-CDG. The company leverages expedited regulatory pathways including Orphan Drug, Fast Track, and Pediatric Rare Disease designations to advance its pipeline.

Is Applied Therapeutics a public or private company?

Applied Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Applied Therapeutics founded?

Applied Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Applied Therapeutics based?

Applied Therapeutics is headquartered in New York, United States, in the North America region.

How does Applied Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Applied Therapeutics's main competitors?

Direct peers on record are Cycle Pharmaceuticals, Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, Recordati Rare Diseases, Travere Therapeutics and Sarepta Therapeutics. Broad incumbents are Alexion (AstraZeneca Rare Disease) and Genzyme (Sanofi). Emerging players are BridgeBio Pharma and Taysha Gene Therapies.

Does Applied Therapeutics have an API?

No public API is recorded for Applied Therapeutics.

What industry is Applied Therapeutics in?

Applied Therapeutics's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldLigand Pharmaceuticals (NASDAQ:LGND) & Applied Therapeutics (NASDAQ:APLT) Head to Head ComparisonLigand Pharmaceuticals and Applied Therapeutics are compared on revenue, earnings, institutional ownership, and analyst ratings. Ligand has higher revenue and earnings, but Applied Therapeutics trades at a lower P/E and has a higher potential upside. Analysts favor Applied Therapeutics due to its higher upside potential.American Banking and Market NewsHead to Head Comparison: Applied Therapeutics (NASDAQ:APLT) vs. Ligand Pharmaceuticals (NASDAQ:LGND)Applied Therapeutics and Ligand Pharmaceuticals are compared on profitability, valuation, and analyst ratings. Ligand has higher revenue and earnings, while Applied trades at a lower P/E. Analysts favor Applied with a higher upside potential.Markets DailyHead to Head Survey: Applied Therapeutics (NASDAQ:APLT) vs. Fate Therapeutics (NASDAQ:FATE)Applied Therapeutics and Fate Therapeutics are compared on profitability, risk, and analyst ratings. Fate Therapeutics beats Applied on 8 of 14 factors, with a consensus price target of $5.90 versus $1.00 for Applied. Analysts favor Applied due to higher potential upside.Ticker ReportComparing Fate Therapeutics (NASDAQ:FATE) and Applied Therapeutics (NASDAQ:APLT)Applied Therapeutics and Fate Therapeutics are compared on financials, ownership, and analyst ratings. Applied has higher earnings but lower revenue, while Fate trades at a lower P/E. Analysts favor Applied with a higher upside potential.Ticker ReportHead to Head Review: Q32 Bio (NASDAQ:QTTB) vs. Applied Therapeutics (NASDAQ:APLT)Q32 Bio and Applied Therapeutics are compared on valuation, earnings, and analyst ratings. Q32 Bio has higher revenue and earnings, while Applied Therapeutics shows higher analyst upside. Q32 Bio beats Applied Therapeutics on 10 of 14 factors.American Banking and Market NewsApplied Therapeutics (NASDAQ:APLT) vs. Krystal Biotech (NASDAQ:KRYS) Financial ComparisonKrystal Biotech and Applied Therapeutics are compared on financial metrics, with Krystal showing higher revenue and earnings but lower analyst ratings. Krystal's beta is 0.5 versus Applied's 2.08, and Krystal beats Applied on 12 of 15 factors. Analysts see higher upside for Applied, but Krystal is more profitable.American Banking and Market NewsFinancial Comparison: Applied Therapeutics (NASDAQ:APLT) and Q32 Bio (NASDAQ:QTTB)A comparison of Q32 Bio and Applied Therapeutics shows Q32 Bio outperforming on 10 of 14 factors, including higher revenue and earnings. Analysts rate Applied Therapeutics more favorably due to a higher potential upside of 870.87% versus Q32 Bio's 265.99%.Ticker ReportCritical Analysis: Applied Therapeutics (NASDAQ:APLT) versus Opus Genetics (NASDAQ:IRD)Opus Genetics and Applied Therapeutics are compared on valuation, risk, earnings, and analyst ratings. Opus Genetics beats Applied Therapeutics on 9 of 15 factors, with higher revenue and lower P/E. Analysts see greater upside in Applied Therapeutics, but Opus is less volatile.Markets DailyComparing Immuron (NASDAQ:IMRN) & Applied Therapeutics (NASDAQ:APLT)MarketBeat.com compared the financial and operational metrics of small-cap healthcare companies Immuron and Applied Therapeutics, analyzing factors such as earnings, valuation, and institutional ownership. The report concluded that Applied Therapeutics holds a stronger consensus rating with significant analyst-upside potential, despite Immuron showing higher revenue figures than its competitor.FamilyWealthReportBenefits Of Investing In Rare Disease Drugs HighlightedA panel debate at the Family Wealth Report Family Office Investment Forum 2026 in New York made the case for rare disease drug development as an investment opportunity for impact-oriented family offices and ultra-high net worth individuals, noting that while each of the roughly 30,000 rare diseases affects a small patient population, they cumulatively impact one in 10 Americans. Participants including representatives from Springhood Ventures, the Orphan Disease Accelerator, Applied Therapeutics, and JK Strategies discussed investment frameworks, platforms such as CGTxchange, and regulatory pathways through US federal healthcare organizations as factors mitigating biotech investment risk. The discussion highlighted rare disease drug development as a space where investors can generate financial returns while fulfilling a social mission.